An international mega-analysis of psychedelic drug effects on brain circuit function
This mega-analysis integrated 11 resting-state MRI datasets on acute effects of psilocybin, lysergic acid diethylamide, mescaline, N,N-dimethyltryptamine and ayahuasca, and found that psychedelics commonly increased connectivity between higher-order and sensory brain networks. It also found altered links involving the thalamus, caudate, putamen and cerebellum, with only modest and variable reductions within networks.
Authors
- Girn, M.
- Doss, M. K.
- Roseman, L.
Published
Abstract
Psychedelic drugs are re-emerging as promising scientific and clinical tools. However, despite a rapidly expanding literature on their therapeutic value, the neural mechanisms underlying psychedelic effects remain unclear. Resting-state functional magnetic resonance imaging studies of acute psychedelic effects, conducted independently by several research groups, have so far yielded fragmented and sometimes inconsistent findings. Here, to help facilitate greater convergence, we conducted a 'mega-analysis' integrating 11 independent resting-state functional magnetic resonance imaging datasets across five psychedelic drugs (psilocybin, lysergic acid diethylamide, mescaline, N,N-dimethyltryptamine and ayahuasca) from research groups spanning three continents and five countries. By applying a uniform preprocessing pipeline and a Bayesian hierarchical modeling framework, we discovered several common features in the induced alterations to brain function across drugs and sites. Most prominently, we identified a core signature of increased functional connectivity between transmodal (default, frontoparietal and limbic) and unimodal networks (visual and somatomotor), with subnetwork specificity. Furthermore, key subcortical regions (thalamus, caudate and putamen) and the cerebellum exhibited altered coupling with sensorimotor networks. In contrast to several single-site reports, Bayesian modeling revealed weak-to-moderate and selective reductions in within-network functional connectivity, with substantial variability across drugs and networks. Together, these findings extend past work by demonstrating that psychedelics reconfigure large-scale cortical organization while selectively engaging subcortical circuitry. This study provides the most comprehensive synthesis of psychedelic brain action to date, helping resolve inconsistencies and offering a probabilistic map of how psychedelics alter large-scale brain organization. We hereby provide a cornerstone to benchmark and shepherd future psychedelic neuroimaging research.
Research Summary of 'An international mega-analysis of psychedelic drug effects on brain circuit function'
Introduction
Girn and colleagues describe a field in which acute psychedelic effects on the brain have been studied with resting-state functional MRI, but the literature has remained fragmented, methodologically variable and sometimes inconsistent. Previous single-site studies had suggested that classic psychedelics may reduce within-network functional connectivity and increase connectivity between large-scale networks, yet the exact network-level pattern varied across datasets, drugs and analysis pipelines. As a result, it was difficult to identify which findings were genuinely reproducible across studies and which might reflect site-specific or methodological differences. The authors set out to address this problem with an international mega-analysis that pooled resting-state functional MRI data across 11 datasets from five psychedelic drugs: psilocybin, LSD, mescaline, DMT and ayahuasca. Their aim was to characterise shared and drug-specific changes in brain circuit function during the acute psychedelic state, using a uniform preprocessing pipeline and Bayesian hierarchical modelling to quantify both effect size and uncertainty. The study is framed as a consortium-based effort to provide a more convergent, probabilistic map of psychedelic brain effects and to establish a benchmark for future neuroimaging research in this area.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- APA Citation
Girn, M., Doss, M. K., Roseman, L., Preller, K. H., Palhano-Fontes, F., Pasquini, L., Barrett, F. S., Mallaroni, P., Mason, N. L., Timmermann, C., McCulloch, D. E., Fisher, P. M., Winston, B. S., Moujaes, F., Muller, F., Liechti, M. E., Vollenweider, F. X., Ramaekers, J. G., Kuypers, K., . . . Bzdok, D. (2026). An international mega-analysis of psychedelic drug effects on brain circuit function. Nature Medicine. https://doi.org/10.1038/s41591-026-04287-9
References (31)
Papers cited by this study that are also in Blossom
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Linguiti, S., Vogel, J. W., Sydnor, V. J. et al. · Neuroscience and Biobehavioral Reviews (2023)
Show all 31 referencesShow fewer
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Avram, M., Müller, F., Rogg, H. et al. · Biological Psychiatry (2022)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.